Dissertations / Theses on the topic 'Endogenous opioids'

Most clinical opioids produce analgesia through the Mu Opioid Receptor (MOR) providing the only effective treatment for chronic pain patients. These studies explore three pre-clinical strategies to improve MOR analgesia and minimize side effects: 1) compounds that target G-protein Coupled Receptors (GPCRs) heterodimers, such as heterodimerization between the Delta Opioid Receptor (DOR) and MOR (MDOR); 2) multi-functional compounds that target multiple receptor systems for synergistic effects, such as a MOR agonist and a the serotonin reuptake transporter (SERT) inhibitor; or 3) biased agonists that preferentially activate one signaling pathway associated with analgesia over another associated with side effects at the same receptor. First, several indirect lines of evidence indicate the MOR-DOR heterodimer (MDOR) can regulate MOR opioid tolerance and withdrawal. However, studying MDOR remains difficult because no selective MDOR antagonists are available. To address this need, we created a novel series of bivalent MDOR antagonists by connecting a low affinity MOR antagonist (H-Tyr-Pro-Phe-D1Nal-NH2) to a moderate affinity DOR (H- Tyr-Tic-OH) antagonist with variable length polyamide spacers (15-41 atoms). In vitro radioligand binding and [35S]-GTPγS coupling assays in MOR, DOR, and MDOR expressing cell lines show bivalent ligands produce a clear length dependence in MDOR but not MOR or DOR cell lines. The lead compound – D24M with a 24-atom spacer – displayed high potency (IC50MDOR = 0.84 nM) with 91-fold selectivity for MDOR:DOR and 1,000-fold MDOR:MOR selectivity. Second, clinicians have long appreciated subtle but distinct differences in analgesia and side effects of MOR opioids. A variety of non-MOR targets including DOR, Kappa Opioid Receptor (KOR), the Cannabinoid Receptor-1 (CB1), the Sigma-1 Receptor (σ1R), the Dopamine- (DAT), Serotonin- (SERT) and Norepinephrine- Reuptake Transporters (NET) induce analgesia and/or modulate MOR mediated side effects. To determine if different opioid profiles arise from non-MOR interactions, we evaluated the binding and function of nine clinical analgesics at the nine aforementioned targets revealing several clinical opioids contain previously unidentified affinity’s or activity’s. Hydrocodone displayed low affinity at the MOR (KI = 1800 nM) and only ~2 fold less affinity at the σ1R (KI = 4000 nM). Second buprenorphine promoted monoamine influx at DAT, SERT and NET with EC50 > 1,000 nM. These novel interactions suggest the nuanced differences of clinical opioids may arise from previously unappreciated off-target effects. Future studies will assess whether these in vitro results predict hydrocodone and buprenorphine activity in vivo. Finally, the unique function of the numerous endogenous opioid peptides at a given receptor remains unclear. How endogenous ligands interact with ORs produces obvious drug design consequences. These studies show two endogenous Dynorphin analogues – Dynorphin A and Dynorphin B – differentially regulate two ubiquitous signaling modules – βarrestin2 and Gαi/o– at the DOR. Dynorphin A and Dynorphin B swap potency rank orders for β-arrestin2 recruitment and [35S]-GTPγS signaling, indicating two distinct signaling platforms are formed. Dynorphin A but not Dynorphin B treatment simulated AC super activation, while Dynoprhin B internalized DOR better than Dynorphin A. These in vitro assays suggest endogenous Dynorphin analogues differentially regulate signals at the DOR in vitro. Future work includes further characterizing signaling differences in vitro and testing these changes in vivo.

In man the metabolic heat produced during physical exercise stresses the thermoregulatory system, particularly if hot, humid environmental conditions prevail. It has recently been postulated that endogenous opioids may play a role in regulating body temperature at rest and because it has also been shown that blood levels of these substances increase during exercise, the possibility exists that endogenous opioids may play a role in thermoregulation during exercise. A study was conducted in two parts to determine the thermoregulatory response during exercise with and without pharmacologic blockade of the opioid receptor. In Part I nine healthy male subjects performed 30 minutes cycling at 50 % maximal aerobic capacity in an environmentally controlled laboratory. The subjects received either placebo, 2mg or 10mg naloxone hydrochloride in a randomized double-blind crossover fashion prior to the exercise test. Rectal temperatures were recorded at one-minute intervals and cardiorespiratory parameters were measured during the test. Water loss was calculated from differences in nude body weight. In part II eight male subjects performed a graded maximal cycle ergometer test after receiving either placebo or 2mg naloxone in a randomized double-blind crossover fashion. Rectal and sublingual temperatures were recorded before and after the test and oesophageal temperature was recorded at one-minute intervals during the test. Cardiorespiratory parameters were recorded during the test. The results of Part I show that rises in rectal temperature as well as calculated water losses were similar for placebo and after the administration of both 2mg and 10mg naloxone. Similarly, during maximal exercise (Part II) the rise in rectal and oesophageal temperatures was equivalent for placebo and 2mg naloxone but sublingual temperature failed to rise during exercise following the 2mg naloxone dose. Cardiorespiratory responses did not differ between placebo and naloxone tests in both Part I and Part II of the study. These results indicate that naloxone-mediated blockade of opioid receptors does not affect rectal and oesophageal temperature responses to either submaximal or maximal exercise. Naloxone appears to selectively alter the sublingual temperature response to exercise possibly by altering local blood flow. It is concluded that insofar as naloxone induced opioid receptor blockade provides a measure of the function of the endogenous opioid system, this study suggests that the endogenous opioid system does not play a significant role in thermoregulation during exercise.

Animal research suggests that exposure to inescapable stressors can lead to an endogenous opioid-mediated form of pain inhibition, known as stress-induced analgesia (SIA). Similar results have been found with humans, although the literature is much less extensive and at times contradictory where uncontrollable stressors have led to an increase, rather than a decrease in pain. More recently, there has been some suggestion that emotions play an important role in pain modulation, and that particular negative moods are associated with opioid-mediated hypoalgesia. This research aimed to clarify the psychological (cognitive and affective) factors underlying endogenous opioid-mediated pain inhibition in humans. The purpose of Study 1 was to examine the effects of stressor controllability and predictability on pain intensity (PI) and unpleasantness (UP) ratings during a cold pressor task (CPT) in 56 male and female subjects. The stressor involved a timed mental arithmetic task during which three moderately noxious electrical shocks were delivered. Although subjects were informed that shock delivery was contingent on math performance, the shock schedule was preset and identical across conditions. Perceived control over the shocks was manipulated between subjects by altering the difficulty of the math task. Shock predictability was manipulated by changing the colour of the computer screen to warn of an impending shock. Subjects were randomly allocated to four experimental conditions (controllable-predictable, controllable-unpredictable, uncontrollable-predictable, and uncontrollable-unpredictable shocks). Visual analogue ratings of 'perceived self-efficacy' (to avoid the shocks) and mood (anxiety, confusion, discouragement, anger, sluggishness, liveliness) were completed before, during and after the math task. Significantly greater discouragement and lower self-efficacy was reported in 'uncontrollable' conditions indicating that 'controllability' was manipulated effectively. Results indicated that a perceived lack of control over shocks during the math task led to significantly greater decreases in PI, but not UP, ratings during the last stages of a 4-minute fixed interval CPT after the math task. Shock predictability failed to influence subjective pain ratings alone; however, unpredictability interacted with lack of control to initially increase pain, followed by analgesia. Stress-induced increases in negative affect (anxiety, discouragement, anger) were associated with decreases in cold pressor PI, but with increased shock PI and UP during the math task. It was concluded that lack of control over an aversive event and negative affect led to SIA during a prolonged pain stimulus, whereas shock predictability had little influence on pain. In Study 2, 70 male and female subjects received either an opioid antagonist (naltrexone) or a placebo before the math task (using a double-blind, counterbalanced design), in order to determine the role of endogenous opioids in SIA. Subjects were randomly assigned to one of three experimental conditions to investigate whether the shocks themselves may have contributed to analgesia observed after the math task: (1) easy task-few shocks, (2) hard task-few shocks, (3) hard task-many shocks. Increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), anxiety, anger and discouragement indicated that negative affect and sympathetic arousal were induced during the math task. Endogenous opioids inhibited the rise in anger, but not discouragement or anxiety, during the math task. There was some evidence that perceived lack of control over shocks, and not the shocks themselves, led to opioid-mediated decreases in cold pressor UP after the math task. In correlational analyses, discouraged subjects under opioid blockade reported more cold pressor UP after the math task than their placebo counterparts. However, this effect was not strong enough to reach statistical significance in regression analyses. Anxiety, anger, discouragement and lack of control over shocks increased shock PI and UP during the math task. A growing body of research with normotensive subjects has linked increased cardiovascular activity with insensitivity to pain, but the role of endogenous opioids remains contentious. In addition to the investigations outlined above, Study 2 aimed to examine the contribution of endogenous opioids in the cardiovascular-pain relationship. However, there was no evidence of an interaction between pain and cardiovascular activity in this study. Study 3 was carried out to investigate opioid involvement in the effects of an uncontrollable stressor and stress-induced negative mood on cold pressor PI, UP and pain tolerance, and onset/thresholds of the nociceptive flexion reflex (RIII). Forty-three male and female subjects were administered either naltrexone or a placebo using a double-blind, counterbalanced design before completing a timed mental arithmetic stressor (identical to the 'hard task-many shocks' condition in Study 2). Increases in physiological (SBP, DBP) and affective measures (anxiety, anger and discouragement) indicated that the math task induced a marked state of stress. Negative affect increased shock PI and UP during the task, whereas self-efficacious subjects taking the placebo experienced less shock pain. However, uncontrollable stress led to an opioid-antagonised increase in cold pressor UP. Stressor controllability had a similar, but marginal, effect on cold pressor PI, but not pain tolerance. Tolerance of cold pressor pain was not associated with subjective PI and UP ratings, but was positively associated with endurance to non-painful, but unpleasant tasks (Valsalva Manoeuvre, Letter-Symbol Matching Task), indicating that pain tolerance was measuring the ability to tolerate discomfort, in addition to pain. Results of hierarchical multiple regressions demonstrated that increases in discouragement were positively related to increases in cold pressor UP after the math task, for naltrexone recipients only. These findings suggest that discouragement inhibits the UP of a prolonged pain stimulus via opioid mechanisms. RIII latencies and thresholds were not affected by the math task or by opioid blockade; however, these null effects may be due to methodological limitations. Unlike Study 2, higher blood pressure was associated with shock and cold pressor pain inhibition in normotensive subjects, and this relationship appeared to be mediated by opioids. The strong association between chronic pain and depression has led to speculation that the endogenous opioid system and pain modulatory mechanisms may be impaired in depression. At the time that this research was carried out, no studies had examined whether this was the case. In Study 4, the effect of a cognitive stressor (math task used in Study 3) on foot cold pressor PI, UP and pain tolerance and the nociceptive, or R2 component, of the blink reflex was investigated in 61 participants with or without major depression (as met by DSM-IV diagnostic criteria and confirmed by psychometric testing). Naltrexone or placebo was administered to subjects an hour before the math task using a double-blind, counterbalanced design. Increases in physiological (SBP, DBP) and affective measures (anxiety, anger and discouragement) confirmed that the math task induced the targeted emotional state. An opioid-mediated reduction in anxiety occurred mid-way through the math task. Opioid-mediated decreases in foot cold pressor PI and UP were observed in depressed and non-depressed subjects after the math task. R2 onset to 10 mA was facilitated after the task regardless of opioid blockade, suggesting that endogenous opioids are not involved in the modulation of the BR. Increased anxiety and discouragement led to opioid-mediated inhibition of shock PI and UP during the task and, to a lesser extent, foot cold pressor PI and UP after the math task. Anger increased shock pain without being influenced by opioid blockade. Pain tolerance was not influenced by depression, opioid blockade or mood. These findings failed to support the idea that SIA is impaired in major depression, suggesting instead that uncontrollable aversive events and negative mood (anxiety, discouragement) lead to opioid activation and insensitivity to acute pain. Multiple regression analyses revealed that the inverse relationship between resting blood pressure and foot cold pressor PI and UP was opioid-mediated in controls only, suggesting that opioid dysregulation in depression might influence regulatory functions other than SIA. In Study 4, opioid involvement in hetero-segmental pain inhibitory phenomena termed diffuse noxious inhibitory controls (DNIC) was examined separately, before psychological stress. Specifically, the effect of a heterotopic noxious conditioning stimulus (CS i.e., hand CPT) on R2 onset latency was compared before and after drug absorption (before the math task). An inhibitory effect of the first CS was detected at each electrical stimulus intensity consistent with a DNIC effect. However, this effect was not detected during the second CS, suggesting that some other process masked the DNIC effect. In summary, the findings indicate that uncontrollable aversive events and negative emotion (primarily discouragement) activates endogenous opioids and inhibits pain in human subjects, whether depressed or not. Notably, opioids inhibited the affective component of pain perception, or pain UP, more consistently than PI, suggesting that the antinociceptive function of opioids may be secondary to an important emotional-modulatory role. Endogenous opioids also appeared to mediate the cardiovascular-pain relationship in normotensive non-depressed subjects, suggesting an important stress-regulatory role for these peptides. Opioid-mediated masking of this relationship in major depression suggests that functioning of the endogenous opioid system may be impaired in baroreceptor-mediated analgesia. This finding provides preliminary support for the notion that opioid antinociceptive system dysfunction may contribute to cardiovascular disease in depression.

Animal research suggests that exposure to inescapable stressors can lead to an endogenous opioid-mediated form of pain inhibition, known as stress-induced analgesia (SIA). Similar results have been found with humans, although the literature is much less extensive and at times contradictory where uncontrollable stressors have led to an increase, rather than a decrease in pain. More recently, there has been some suggestion that emotions play an important role in pain modulation, and that particular negative moods are associated with opioid-mediated hypoalgesia. This research aimed to clarify the psychological (cognitive and affective) factors underlying endogenous opioid-mediated pain inhibition in humans. The purpose of Study 1 was to examine the effects of stressor controllability and predictability on pain intensity (PI) and unpleasantness (UP) ratings during a cold pressor task (CPT) in 56 male and female subjects. The stressor involved a timed mental arithmetic task during which three moderately noxious electrical shocks were delivered. Although subjects were informed that shock delivery was contingent on math performance, the shock schedule was preset and identical across conditions. Perceived control over the shocks was manipulated between subjects by altering the difficulty of the math task. Shock predictability was manipulated by changing the colour of the computer screen to warn of an impending shock. Subjects were randomly allocated to four experimental conditions (controllable-predictable, controllable-unpredictable, uncontrollable-predictable, and uncontrollable-unpredictable shocks). Visual analogue ratings of 'perceived self-efficacy' (to avoid the shocks) and mood (anxiety, confusion, discouragement, anger, sluggishness, liveliness) were completed before, during and after the math task. Significantly greater discouragement and lower self-efficacy was reported in 'uncontrollable' conditions indicating that 'controllability' was manipulated effectively. Results indicated that a perceived lack of control over shocks during the math task led to significantly greater decreases in PI, but not UP, ratings during the last stages of a 4-minute fixed interval CPT after the math task. Shock predictability failed to influence subjective pain ratings alone; however, unpredictability interacted with lack of control to initially increase pain, followed by analgesia. Stress-induced increases in negative affect (anxiety, discouragement, anger) were associated with decreases in cold pressor PI, but with increased shock PI and UP during the math task. It was concluded that lack of control over an aversive event and negative affect led to SIA during a prolonged pain stimulus, whereas shock predictability had little influence on pain. In Study 2, 70 male and female subjects received either an opioid antagonist (naltrexone) or a placebo before the math task (using a double-blind, counterbalanced design), in order to determine the role of endogenous opioids in SIA. Subjects were randomly assigned to one of three experimental conditions to investigate whether the shocks themselves may have contributed to analgesia observed after the math task: (1) easy task-few shocks, (2) hard task-few shocks, (3) hard task-many shocks. Increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), anxiety, anger and discouragement indicated that negative affect and sympathetic arousal were induced during the math task. Endogenous opioids inhibited the rise in anger, but not discouragement or anxiety, during the math task. There was some evidence that perceived lack of control over shocks, and not the shocks themselves, led to opioid-mediated decreases in cold pressor UP after the math task. In correlational analyses, discouraged subjects under opioid blockade reported more cold pressor UP after the math task than their placebo counterparts. However, this effect was not strong enough to reach statistical significance in regression analyses. Anxiety, anger, discouragement and lack of control over shocks increased shock PI and UP during the math task. A growing body of research with normotensive subjects has linked increased cardiovascular activity with insensitivity to pain, but the role of endogenous opioids remains contentious. In addition to the investigations outlined above, Study 2 aimed to examine the contribution of endogenous opioids in the cardiovascular-pain relationship. However, there was no evidence of an interaction between pain and cardiovascular activity in this study. Study 3 was carried out to investigate opioid involvement in the effects of an uncontrollable stressor and stress-induced negative mood on cold pressor PI, UP and pain tolerance, and onset/thresholds of the nociceptive flexion reflex (RIII). Forty-three male and female subjects were administered either naltrexone or a placebo using a double-blind, counterbalanced design before completing a timed mental arithmetic stressor (identical to the 'hard task-many shocks' condition in Study 2). Increases in physiological (SBP, DBP) and affective measures (anxiety, anger and discouragement) indicated that the math task induced a marked state of stress. Negative affect increased shock PI and UP during the task, whereas self-efficacious subjects taking the placebo experienced less shock pain. However, uncontrollable stress led to an opioid-antagonised increase in cold pressor UP. Stressor controllability had a similar, but marginal, effect on cold pressor PI, but not pain tolerance. Tolerance of cold pressor pain was not associated with subjective PI and UP ratings, but was positively associated with endurance to non-painful, but unpleasant tasks (Valsalva Manoeuvre, Letter-Symbol Matching Task), indicating that pain tolerance was measuring the ability to tolerate discomfort, in addition to pain. Results of hierarchical multiple regressions demonstrated that increases in discouragement were positively related to increases in cold pressor UP after the math task, for naltrexone recipients only. These findings suggest that discouragement inhibits the UP of a prolonged pain stimulus via opioid mechanisms. RIII latencies and thresholds were not affected by the math task or by opioid blockade; however, these null effects may be due to methodological limitations. Unlike Study 2, higher blood pressure was associated with shock and cold pressor pain inhibition in normotensive subjects, and this relationship appeared to be mediated by opioids. The strong association between chronic pain and depression has led to speculation that the endogenous opioid system and pain modulatory mechanisms may be impaired in depression. At the time that this research was carried out, no studies had examined whether this was the case. In Study 4, the effect of a cognitive stressor (math task used in Study 3) on foot cold pressor PI, UP and pain tolerance and the nociceptive, or R2 component, of the blink reflex was investigated in 61 participants with or without major depression (as met by DSM-IV diagnostic criteria and confirmed by psychometric testing). Naltrexone or placebo was administered to subjects an hour before the math task using a double-blind, counterbalanced design. Increases in physiological (SBP, DBP) and affective measures (anxiety, anger and discouragement) confirmed that the math task induced the targeted emotional state. An opioid-mediated reduction in anxiety occurred mid-way through the math task. Opioid-mediated decreases in foot cold pressor PI and UP were observed in depressed and non-depressed subjects after the math task. R2 onset to 10 mA was facilitated after the task regardless of opioid blockade, suggesting that endogenous opioids are not involved in the modulation of the BR. Increased anxiety and discouragement led to opioid-mediated inhibition of shock PI and UP during the task and, to a lesser extent, foot cold pressor PI and UP after the math task. Anger increased shock pain without being influenced by opioid blockade. Pain tolerance was not influenced by depression, opioid blockade or mood. These findings failed to support the idea that SIA is impaired in major depression, suggesting instead that uncontrollable aversive events and negative mood (anxiety, discouragement) lead to opioid activation and insensitivity to acute pain. Multiple regression analyses revealed that the inverse relationship between resting blood pressure and foot cold pressor PI and UP was opioid-mediated in controls only, suggesting that opioid dysregulation in depression might influence regulatory functions other than SIA. In Study 4, opioid involvement in hetero-segmental pain inhibitory phenomena termed diffuse noxious inhibitory controls (DNIC) was examined separately, before psychological stress. Specifically, the effect of a heterotopic noxious conditioning stimulus (CS i.e., hand CPT) on R2 onset latency was compared before and after drug absorption (before the math task). An inhibitory effect of the first CS was detected at each electrical stimulus intensity consistent with a DNIC effect. However, this effect was not detected during the second CS, suggesting that some other process masked the DNIC effect. In summary, the findings indicate that uncontrollable aversive events and negative emotion (primarily discouragement) activates endogenous opioids and inhibits pain in human subjects, whether depressed or not. Notably, opioids inhibited the affective component of pain perception, or pain UP, more consistently than PI, suggesting that the antinociceptive function of opioids may be secondary to an important emotional-modulatory role. Endogenous opioids also appeared to mediate the cardiovascular-pain relationship in normotensive non-depressed subjects, suggesting an important stress-regulatory role for these peptides. Opioid-mediated masking of this relationship in major depression suggests that functioning of the endogenous opioid system may be impaired in baroreceptor-mediated analgesia. This finding provides preliminary support for the notion that opioid antinociceptive system dysfunction may contribute to cardiovascular disease in depression.

This work is focused in the study of the pathophysiology of neuropathic pain, particularly in the role of the endogenous opioid and cannabinoid systems. Neuropathic pain is a chronic illness with a high prevalence in the population and is characterized by the presence of spontaneous pain and abnormal stimulus-evoked pain responses, among other symptoms. It is a clinical pain manifestation that has shown to be poorly treated with the available pharmacological treatment. Even with the existence of many therapeutic approaches, there is not an adequate effective treatment for palliating all symptoms of neuropathic pain. This situation leads us to study the specific involvement of the endogenous opioid and cannabinoid systems in the pathophysiology of the development and maintenance of neuropathic pain. In the present study, we have evaluated the role of delta opioid receptor (DOR) in the central nervous system (CNS) and peripheral nociceptive neurons, as well as the participation of cannabinoid receptor type 2 (CB2) in the activated microglia at the spinal cord. The results show that DOR and CB2 may be pharmacological targets for the development of new drugs with analgesic activity, but devoid of the psychotropic side effects of traditional opioids and cannabinoid agonists.<br>Aquest treball es centra en l’estudi de la fisiopatologia del dolor neuropàtic, en particular en el paper dels sistemes endògens opioide i cannabinoide. El dolor neuropàtic és una malaltia crònica amb una alta prevalença en la població i es caracteritza per la presència de dolor espontani i percepció anormal del dolor, entre d’altres símptomes. És una manifestació clínica del dolor que ha demostrat ser mal tractada amb el tractament farmacològic disponible. Malgrat l’existència de molts enfocs terapèutics, no hi ha un tractament eficaç adequat per pal•liar els símptomes del dolor neuropàtic. Aquesta situació ens porta a estudiar la participació específica dels sistemes endògens opioide i cannabinoide en la fisiopatologia del desenvolupament i manteniment del dolor neuropàtic. En el present estudi, hem avaluat el paper del receptor opioide delta (DOR) en el sistema nerviós central (SNC) i perifèric en neurones nociceptives, així com la participació dels receptors cannabinoides tipus 2 (CB2) a la micròglia activada a la medul•la espinal. Els resultats mostren que DOR i CB2 poden ser dianes farmacològiques per al desenvolupament de nous fàrmacs amb activitat analgèsica, però amb menys efectes psicotròpics secundaris dels opioides tradicionals i els agonistes cannabinoides.

Four studies were conducted to investigate the effect and site of action of exogenous and endogenous opioids on pituitary growth hormone (GH) and prolactin (PRL) secretion in Holstein calves. In the first study, the effect of the opioid agonist DAMME (D-Ala²⁺,N-Me-Phe⁴,Met(O)⁵-01 enkephalin) on plasma GH and PRL secretion was measured in Holstein calves in fall season. Plasma concentrations of both GH and PRL increased in response to DAM ME injection. Pretreatment with either the lipid soluble opioid antagonist naloxone (NAL), which readily penetrates the blood brain barrier (BBB), or the peripherally acting antagonist methyl levallorphan mesiltate (MLM), blocked the PRL response to DAMME. Naloxone, but not MLM, negated the GH response to DAMME. In spring, the experiment was repeated with similar results. In the second experiment, the opioid antagonists NAL and MLM were administered alone to detennine whether endogenous opioids mediate basal GH and PRL secretion, and the site of action of any of opioid-mediation of basal GH and PRL. In fall, NAL administration increased both plasma GH and PRL secretion. Methyl levallorphan mesilate did not affect PRL, but increased plasma GH concentrations. In spring, a second trial using 5 different doses of each antagonist was conducted. Naloxone did not affect GH levels at any dose in spring, but decreased plasma PRL at the same dose which increased plasma PRL in fall. Plasma PRL was again unaffected by MLM, but plasma GH was increased by 3 separate doses of MLM. The third experiment was designed to determine if the increases in plasma PRL seen after DAMME administration were mediated via dopaminergic mechanisms. Plasma PRL in calves again increased in response to DAMME injection alone. In calves pre-treated with the long-acting dopamine agonist 2-Br-&alp. ergocryptine (CB 154), plasma PRL was unresponsive to DAMME injection. The pituitaries of calves treated with CB 154 in this experiment were able to respond to thyrotropin-releasing hormone (TRH) injection with increased PRL secretion. In the final experiment, the role of growth hormone-releasing hormone (GRH) in facilitating GH release after DAMME injection was investigated, and whether endogenous opioidergic mechanisms play a role in mediating the effects of exogenous GRH on GH secretion. Plasma GH concentrations increased in calves receiving either DAMME or D-ala²⁺, fragment 1- 29 amide, a synthetic GRH. The immediate increase in plasma GH concentrations after GRH injection in calves pre-treated with DAMME was approximately 5 fold less than that in calves not pre- treated with DAMME. Calves receiving DAMME and GRH in combination also produced a GH response curve with greater area under it than either compound alone, indicating possible synergism between the synthetic GRH and a DAMME-sustained release of endogenous GRH. Naloxone administration concomitantly with synthetic GRH did not alter the ability of the synthetic GRH to increase GH secretion overall, compared to synthetic GRH alone. In conclusion, these studies are the first to indicate that dairy breeds are able to respond to exogenous opioids with increased secretion of pituitary GH and PRL, as is known to occur in other mammalian species. Also, they indicate that opioid receptors mediating pituitary GH secretion to exogenous opioids in Holstein calves are located somewhere within the BBB, and those mediating PRL secretion are at a site outside the BBB. It appears from these studies that endogenous opioids within the BBB play a role in regulating basal PRL secretion, and that this regulation differs in fall and spring. A role for endogenous opioids in the regulation of GH secretion in Holstein calves may exist also, at least in fall, but the results are less conclusive. The peripheral opioid antagonist MLM alone may facilitate increased GH secretion in Holstein calves via an agonistic, not antagonistic, mechanism. These studies indicate that the increased PRL secretion seen following opioid administration in Holstein calves is mediated through a dopaminergic mechanism. It appears that endogenous opioids do not mediate the pituitary response to exogenous GRH in Holstein calves, and that GH increases after DAMME injection are facilitated, at least in part, by increased release of endogenous GRH.<br>Ph. D.

The binding of [³H]opioid ligands to homogenates prepared from the spinal cords of rat and other species has been studied. Similar numbers of sites were seen in all areas of the cord when measured in a rostrocaudal direction. There was found to be approximately 2 x higher density of sites in the dorsal half of the cord compared with the ventral half. Binding studies suggested a similar relative distribution of mu, delta and kappa sites in all areas of the cord. The results are discussed in relation to the reported distribution of opioid peptides. In the above study the kappa binding site was defined as the binding of [³H] unselective opioids in the presence of cold ligands to suppress binding to mu- and delta-sites. Competitive binding assays, however, suggested this site did not have the properties of a single homogeneous group. Approximately 50% of the apparent kappa binding was consistent with a classical kappa site. Saturated binding assays afforded Bmax values which suggested lower 'true' kappa site numbers than previously supposed, values which were confirmed using the kappa peptide' [³H]Dynorphin A-(1-9), and the kappa selective [³H]U-69593. Heterogeneity was also seen in other central nervous system tissues. The heterogeneous nature of the kappa site may be due to different sites, due to interactions at a non-opioid site or may represent different conformations of the same site. The second possibility was discounted since observed binding followed the cellular distribution of the plasma marker Na+/K+-ATPase was stereoselective for levorphanol over dextrorphan, and fully displaceable by naloxone. The third possibility was investigated by studying the role of Na+ and MG2+ ions, which are reported to affect receptor conformation in binding assays employing brain tissues. None of the results obtained suggested that conformational changes were responsible for the observed effects, although the experiments were not exhaustive.

Placebo treatments are inert but are known to alleviate symptoms across numerous clinical conditions. One of the most studied placebo effects is placebo analgesia, which is a placebo effect limited to pain relief. This thesis aims to introduce the current state of research regarding the neuroscience of placebo analgesia and specifically to present research findings regarding the neurotransmission. Studies have demonstrated that placebo analgesia can be elicited through two separate processes interacting with each other; manipulation of expectations and through conditioning. These processes seem to affect neurotransmission in different ways. Many brain areas have been found to be correlated to placebo analgesia. Besides the pain-processing brain areas, studies point to that the prefrontal cortex can have a vital role in the placebo analgesic effect. Known neurotransmitters that have shown to be involved in placebo analgesia are endogenous opioids, cholecystokinin (CCK), and endocannabinoids. Studies point to that endogenous opioids are involved in the placebo analgesic effect when elicited by expectation or conditioned by an opioid drug. CCK act on placebo analgesia by affecting the release of endogenous opioids and endocannabinoids seem to be involved in placebo analgesia while it occurs due to conditioning with non-opioid drugs. Getting a better understanding of placebo analgesia and find ways to apply this knowledge in the clinical context could powerfully develop the whole medical society.

Myelin is an extensive cell membrane produced by oligodendrocytes to ensheath neuronal axons in the central nervous system with the primary goal of maximizing the efficiency of electrochemical impulse transmission. During brain development, oligodendrocytes differentiate into myelin forming cells in a tightly regulated process which makes them vulnerable to multiple insults. Previous results from the laboratory showed that the timing of oligodendrocyte differentiation and rat brain myelination were altered by perinatal exposure to buprenorphine and methadone, opioid analogues used for treating pregnant addicts. The mechanism by which these opioids exerted their effects involved two opioid receptors, the μ-opioid receptor (MOR) and the nociceptin/orphanin FQ receptor (NOR). However, the role of these receptors and their endogenous ligands in controlling the timing of myelination under normal physiological conditions of brain development is not known. In this dissertation, we found that the endogenous MOR ligand endomorphin-1 (EM-1) acts as a strong promoter of rat pre-oligodendrocyte differentiation, but surprisingly, this effect is observed only in cells isolated from female pups. Interestingly, the stimulatory action of EM-1 was abolished upon co-incubation with the endogenous NOR ligand, nociceptin. Moreover, injections of NOR antagonist to 9-day-old female and male rat pups accelerated rat brain myelination in female rat pups with no significant changes in their male counterparts. Interestingly, the lack of major sex-dependent differences in developmental brain levels of EM-1 and nociceptin and the presence of the two receptors MOR and NOR in male and female oligodendrocytes suggested that the observed sex-specific responses may be highly dependent on critical intrinsic sex-dependent differences within these cells. Although nociceptin alone did not exert observable effects on pre-oligodendrocyte maturation, it increased the number of cells expressing Ki-67, a cell proliferation indicator, in oligodendrocyte progenitor cultures. These results suggest that nociceptin may be playing a stage specific role in oligodendrocyte development during brain maturation. The finding of critical functions of EM-1 and nociceptin in the developing female oligodendrocytes and brain myelination highlights the need for considering sexual dimorphism in the design of safer and more effective therapeutic approaches for treating opioid abuse, pain, and demyelinating disease as multiple sclerosis.

The opioid receptors and their endogenous ligands have long been implicated in a variety of traits including addiction, impulsive behaviors and substance dependence. Using phenotypic measurements collected from the IASPSAD, data from a latent class analysis and data from a SNP array and additional genotyping assays, association and regression tests were performed to determine the effects of common SNPs encoded in the genes of the opioid receptors and ligands on various traits relating to alcohol dependence. Although only one SNP can be reported as significant for substance dependence within alcoholics, there were a few results approaching significance that may offer some insight into variation within alcoholism.

Thesis (Ph. D.)--Georgia State University, 2008.<br>Title from title page (Digital Archive@GSU, viewed June 16, 2010) Anne Z. Murphy, committee chair; Timothy Bartness, Matthew Grober, Michael Gold, Charles Derby, committee members. Includes bibliographical references (p. 148-164).

Bases: A antinocicepção induzida por substâncias doces tem sido largamente estudada. Contudo, a investigação dos neurotransmissores envolvidos nesse processo antinociceptivo ainda carece de mais estudos, pois é de extrema importância entender o envolvimento desses neurotransmissores no sistema neural que controla este tipo de antinocicepção. Objetivo: O objetivo deste estudo é clarificar o envolvimento dos sistemas opióide e serotoninérgico na antinocicepção induzida por substância doce. Método: O presente trabalho foi realizado em modelo animal (Rattus norvegicus, Rodentia, Muridae), objetivando investigar se a ingestão crônica de solução de sacarose é seguida de antinocicepção. A latência de retirada de cauda após a aplicação de estímulo nocivo térmico foi medida antes e após esse tratamento no teste de retirada de cauda (provavelmente um reflexo espinal). Não houve diferenças estatisticamente significantes entre os valores de linha basal dos diferentes grupos e foi calculado um índice de analgesia da latência de retirada de cauda antes e depois do tratamento. O envolvimento de opióides endógenos e de serotonina neste processo antinociceptivo foi pesquisado com fármacos antagonistas específicos e não-específicos dos receptores opióides e serotoninérgicos. Resultados: O efeito analgésico da ingestão de sacarose depende da concentração da solução de sacarose e do tempo de duração do consumo da mesma. Naltrexona e metisergida diminuíram a antinocicepção induzida por substâncias doce (após 14 dias de ingestão da sacarose). Estes efeitos foram corroborados pela administração periférica de naloxonazina e cetanserina. Conclusões: Os resultados sugerem o envolvimento de opióides endógenos e serotonina no processo antinociceptivo atualmente estudado. Tudo apontando para a participação de receptores opióides µ1 e serotoninérgicos 5-HT2 na regulação central da antinocicepção induzida por substâncias doces.<br>Rationale: Sweet substance-induced antinociception has been widely studied, and the investigation of the neurotransmitters involved in the antinociceptive process is an important way for understanding the involvement of neural system controlling this kind of antinociception. Objective: The aim of this study is to investigate the involvement of opioid and serotonergic system in the sweet substance-induces antinociception. Methods: the present work was made in animal model (Rattus norvegicus, Rodentia, Muridae); with the aim of investigating if the chronic intake of sweet substance, such as sucrose, is followed by antinociception. Their tail withdrawal latencies in the tail-flick test (probably a spinal reflex) were measured before and immediately after this treatment. As there was not statistic significant differences between baseline values of different groups, an analgesia index was calculated from the withdrawal latencies before and after treatment. The involvement of endogenous opioid and serotonin in the antinociceptive process was investigated with specific and non-specific pharmacological antagonism on opioid and serotonergic receptors. Results: The analgesic effect of sucrose intake depends on the concentration of sucrose solution and on the time during which the solution is consumed. Naltrexone and methysergide decreased the sweet substance-induced antinociception (post 14 days of sucrose intake). These effects were corroborated by peripheral administration of naloxonazina and ketanserin. Conclusions: The present results suggest the involvement of endogenous opioids and serotonin in the antinociceptive process presently studied. µ1-opioid and 5-HT2 serotonergic receptors may be involved in the central regulation of the sweet substance-produced antinociception.

Delta9-tetrahydrocannbinol (THC), the primary active constituent of Cannabis sativa, has long been known to reduce opioid withdrawal symptoms. Although THC produces most of its pharmacological actions through the activation of CB1 and CB2 cannabinoid receptors, the role these receptors play in reducing opioid withdrawal symptoms remains unknown. The endogenous cannabinoids, N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonylglycerol (2-AG), activate both cannabinoid receptors, but are rapidly metabolized by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. The objective of this dissertation was to test whether increasing AEA or 2-AG, via inhibition of their respective hydrolytic enzymes, reduces morphine withdrawal symptoms in in vivo and in vitro models of opiate dependence. Morphine-dependent ICR mice subjected to acute naloxone challenge or abrupt withdrawal (via pellet removal) reliably displayed a profound withdrawal syndrome, consisting of jumping, paw tremors, head shakes, diarrhea, and weight loss. THC and the MAGL inhibitor, JZL184 dose-dependently reduced the intensity of precipitated withdrawal measures through the activation of CB1 receptors. The FAAH inhibitor, PF-3845, reduced the intensity of a subset of precipitated signs through the activation of CB1 receptors, but did not ameliorate the incidence of diarrhea or weight loss. In the next set of experiments, MAGL inhibition dose-dependently reduced the intensity of all spontaneous withdrawal signs (i.e jumps, paw flutters, head shakes, weight loss and diarrhea) in a CB1 receptor dependent manner. However, FAAH inhibition reduced the intensity of head shakes and paw flutters, but did not affect other signs. Strikingly, a combination of low-dose JZL184 and high-dose PF-3845 reduced abrupt withdrawal signs in a manner similar to complete MAGL inhibition, which suggests potential therapeutic advantages of dual enzyme inhibition. This combination elevated appropriate eCB levels and caused moderate CB1 receptor desensitization, but did not affect receptor number in whole brain. Since MAGL, but not FAAH inhibition, blocked diarrhea during opioid withdrawal in vivo, we investigated whether inhibitors of each enzyme would differentially attenuate naloxone-precipitated contractions and secretion in morphine-dependent ilea in vitro. Both enzyme inhibitors attenuated the intensity of naloxone-induced contractions, and blocked naloxone-precipitated hypersecretion. Thus, these models offer useful tools for investigating in vitro end-ponts of withdrawal, but not for elucidating anti-diarrheal mechanism of these inhibitors.If targeting endocannabinoid catabolic enzymes is indeed a viable approach to treat other abuse disorders, it is important to know whether these inhibitors would themselves have abuse or dependence liability. In the final series of experiments we tested whether prolonged elevation of endocannabinoid leads to the development of cannabinoid dependence, based on the occurrence of somatic withdrawal signs upon challenge with rimonabant, a CB1 receptor antagonist. Repeated treatment with high doses, but not low doses, of JZL184 led to cannabinoid dependnece. These results indicate that the strategy of increasing endogenous cannabinoids through the inhibition of their catabolic enzymes represents a promising approach to ameliorate opioid withdrawal symptoms.

Tese (doutorado) - Universidade de São Paulo. Departamento de Fisiologia e Biofisica<br>Made available in DSpace on 2012-10-16T02:39:44Z (GMT). No. of bitstreams: 0Bitstream added on 2013-07-16T17:11:53Z : No. of bitstreams: 1 79070.pdf: 3225953 bytes, checksum: ea81b1737299aba3fa4afaa0e98c7d30 (MD5)

Genes and environment interact to determine an individual’s vulnerability or resilience to several psychiatric disorders, including alcohol use disorder (AUD). Alcohol use is often initiated during adolescence and early onset drinking is associated with increased risk for later AUD. Childhood and adolescence are periods of extensive brain maturation, which makes young individuals more susceptible to environmental influence. However, little is known about early environmental influence on reward pathways and behaviors involved in the development of AUD. Changes in the endogenous opioid and dopamine systems, as well as individual differences in risk behaviors are all believed to play important roles in the increased vulnerability seen after adverse early life events and early onset drinking. The overall aim of the thesis was therefore to investigate the influence of early environmental factors on adolescent alcohol intake, endogenous opioids, dopamine dynamics and alcohol-induced effects in rats to increase our knowledge of neurobiological factors underlying vulnerability to AUD. Furthermore, individual behavioral differences and their correlation to basal and drug-induced neurobiological responses in rats were also investigated. Animal models of different early environments, e.g. maternal separation and social vs. single housing, and adolescent alcohol consumption have been used to study effects on behavior, endogenous opioid peptides and dopamine dynamics. The results identified the amygdala and dorsal striatum as interesting brain regions in which endogenous opioids and dopamine, respectively, are impacted by early environmental factors. The amygdala and the dorsal striatum are both hypothesized to be involved in the shift from initial drug use to compulsive use and changes in these areas may be underlying environmentally increased vulnerability to AUD. Furthermore, behavioral phenotypes in relation to individual neurobiological responses were identified. High risk-taking behavior was associated with a more pronounced response to amphetamine, but the inherent dopamine response was instead associated with risk-assessment behavior. In conclusion, several brain regions of interest for future research were identified. Furthermore, the results contribute to increased understanding of factors involved in the development of vulnerability for AUD in adolescents and young adults.

The interaction of a diverse set of opioid alkaloids and peptides with various opioid receptors has been examined using biochemical and pharmacological techniques. Structural information on the compounds was obtained from single crystal X-ray diffraction and nuclear magnetic resonance studies, and modelled by computational methods. The introduction of a dithiocarbazate moiety into the 7a-position of a bridged thebaine was shown to afford a degree of μ selectivity in this class of nonselective compounds. X-ray diffraction analysis of this compound and comparison with the structure of [Met5]enkephalin showed the importance of the sulphydryl moiety. The conformation of [Leu5]enkephalin, in which the amino acid methionine is replaced by leucine, at the same receptor is unlikely to be similar. A series of morphinan derivatives which had been developed as μ-antagonists were evaluated. Substitution patterns of the morphinan ring nucleus and their effect upon activity were examined. X-ray analysis of several key compounds was performed. Unexpectedly a 3-hydroxymorphinan-6-one analogue showed an ability to differentiate apparently similar opioid Kreceptors. The implications in terms of K-receptor subtypes are discussed. The opioid receptor binding characteristics of structurally diverse K-receptor ligands were examined in two different buffer systems. Electrostatic modelling of the K-ligands, based upon crystal structure coordinates, was performed. From electrostatic potential maps a requirement for ligands acting at Kreceptors is postulated. Solution conformations of the endogenous K-ligand, dynorphin A(1-8), were determined by nuclear magnetic resonance studies and compared with the wo preferring [Leu5]enkephalin. Models were proposed based upon dihedral angles determined from HCtl-NH coupling constants, amide proton-deuteron exchange and amide proton temperature coefficient data. Candidate conformations were shown to be stable under dynamic simulation conditions. Electrostatic modelling of a chosen dynorphin An-8) conformation gave results comparable with the observed electrostatic model of the K-ligands. The proposed model is discussed in terms of its suitability as a retro-model for the active site ofthe K-opioid receptor.

Thesis (Ph. D.)--Ohio State University, 2004.<br>Title from first page of PDF file. Document formatted into pages; contains xiii, 172 p.; also includes graphics (some col.). Includes bibliographical references (p. 131-172 ). Available online via OhioLINK's ETD Center

The endogenous opioid system may be involved in the pathogenesis of arrhythmias and produce deleterious haemodynamic effects in patients with myocardial ischaemia and/or cardiac failure. Plasma concentrations of β-endorphin, a potent opioid peptide, were elevated in 31/42 patients with acute myocardial infarction, 3/18 with unstable angina, 3/34 with chronic heart failure, 8/28 with acute heart failure and 10/14 with cardiogenic shock. (Met)enkephalin levels were generally normal. There was no independent statistical relationship between β-endorphin concentrations after myocardial infarction and the incidence of cardiac arrhythmias. In isolated myocardium, the opioid antagonists naloxone and nalmafene, and morphine, an agonist, all produced Class III antiarrhythmic effects. Naloxone enhanced the reduction in maximum upstroke velocity produced by hyperkalaemia and post-repolarization refractoriness developed. During myocardial ischaemia the Class III effects of naloxone were gradually lost but both racemic naloxone (active at opioid receptors) and d-naloxone (inactive) reduced the rate of rise of extracellular potassium concentration and preserved resting membrane potential. The fall in maximum upstroke velocity during ischaemia was enhanced by both compounds suggesting an additional Class I effect. In human studies, despite employing high doses of naloxone, it was only possible to show a minor prolongation of repolarization. In patients with coronary heart disease, naloxone administered by both intracoronary and intravenous routes had no effect on coronary blood flow. In patients with heart failure naloxone had no significant effects on a range of haemodynamic parameters, exercise performance or levels of dyspnoea and fatigue.

Thesis (Ph.D)--Tufts University, 2000.<br>Adviser: Robin B. Kanarek. Submitted to the Dept. of Psychology. Includes bibliographical references (leaves 109-134). Access restricted to members of the Tufts University community. Also available via the World Wide Web;

The increase incidence of obesity and eating disorders represents a major health problem in developed countries. The low rate of success of treatments to prevent or reverse obesity, and overeating that causes it, highlights the important behavioural alterations that are associated to this disease. These alterations seem to be mediated by modifications in the reward circuits that mimic changes occurring during addictive behaviour. Moreover, like drugs of abuse, obesity is associated with abnormal intake habits when maintaining diet that can endure vulnerability to relapse. In the present thesis, we have first investigated the involvement of the endogenous opioid system in the neurobiological mechanism underlying drug and food reinstatement, as a potential therapeutic target in these behavioural disorders. Moreover, we have investigated the relationships between overeating and behavioural addiction. Indeed, we have demonstrated that repeated operant training with palatable food promotes behavioural alterations, as well as epigenetic, proteomic and structural plasticity changes in the reward circuit reminiscent to those observed with drugs of abuse. Finally, we identified the cannabinoid receptor 1 and the delta opioid receptor as common neurobiological substrates underlying these alterations.<br>El aumento de la incidencia de la obesidad y de los trastornos de la alimentación representa un importante problema de salud en los países desarrollados. La baja tasa de éxito de los tratamientos disponibles para prevenir o revertir la obesidad y el fácil acceso a la comida obesogenica que lo causa, destacan la necesidad de encentrar dianas terapéuticas eficaces. Las importantes alteraciones conductuales que se asocian a esta enfermedad parecen estar mediadas por modificaciones en los circuitos de recompensa que imitan los cambios que ocurren durante el comportamiento adictivo. Por otra parte, al igual que las drogas de abuso, la obesidad se asocia con hábitos de ingesta anormales que pueden incrementar la vulnerabilidad a la recaída de búsqueda de comida. En la presente tesis, hemos investigado primero la implicación del sistema opioide endógeno en el mecanismo neurobiológico que subyace a la recaída del comportamiento de búsqueda de drogas y comida como una posible diana terapéutica en estos trastornos del comportamiento. En segundo lugar, hemos investigado las relaciones entre la sobre ingesta de comida palatable y la adicción conductual. De hecho, hemos demostrado que el entrenamiento operante repetido con comida palatable promueve alteraciones de la conducta, así como cambios epigenéticos, proteómicos y de plasticidad estructural en el circuito de la recompensa que recuerdan a los observados con las drogas de abuso. Es destacable señalar que hemos identificado el vii receptor cannabinoide 1 y el receptor delta opioide como sustratos neurobiológicos comunes que subyacen a estas alteraciones.

The aims of the thesis were to examine i) whether the endogenous opioid system (EOS) is lateralized in human brain areas involved in processing of emotions and pain; ii) whether EOS responses to unilateral brain injury depend on side of lesion, and iii) whether in human alcoholics, this system is involved in molecular adaptations in brain areas relevant for cognitive control of addictive behavior and habit formation. The main findings were that (1) opioid peptides but not opioid receptors and classic neurotransmitters are markedly lateralized in the anterior cingulate cortex involved in processing of  positive and negative emotions and affective component of pain. The region-specific lateralization of neuronal networks expressing opioid peptides may underlie in part lateralization of higher functions in the human brain including emotions and pain. (2) Analysis of the effects of traumatic brain injury (TBI) demonstrated predominant alteration of dynorphin levels in the hippocampus ipsilateral to the injury, while injury to the right hemisphere affected dynorphin levels in the striatum and frontal cortex to a greater extent than that to the left hemisphere. Thus, trauma reveals a lateralization in the mechanisms mediating the response of dynorphin expressing neuronal networks in the brain. These networks may differentially mediate effects of left or right brain injury on lateralized brain functions. (3) In human alcoholics, the enkephalin and dynorphin systems were found to be downregulated in the caudate nucleus and / or putamen that may underlie in part changes in goal directed behavior and formation of a compulsive habit in alcoholics. In contrast to downregulation in these areas, PDYN mRNA and dynorphins in dorsolateral prefrontal cortex, k-opioid receptor mRNA in orbitofrontal cortex, and dynorphins in hippocampus were upregulated in alcoholics. Activation of the k-opioid receptor by upregulated dynorphins may underlie in part neurocognitive dysfunctions relevant for addiction and disrupted inhibitory control. We conclude that the EOS exhibits region-specific lateralization in human brain and brain-area specific lateralized response after unilateral TBI in mice; and that the EOS is involved in adaptive processes associated with specific aspects of alcohol dependence.

Alcohol abuse and addiction are among the most costly and prevalent behavioural disorders due to the drug's reinforcing potential and ubiquity in society. Studies suggest an interaction between alcohol and the endogenous opioid system: manipulation of endogenous opioid activity affects alcohol intake, and alcohol administration alters endogenous opioid activity. However, the data are inconclusive given the discrepancy between pharmacological and genetic knockout studies on alcohol intake, and the difficulty in interpreting and replicating findings determined postmortem.<br>There were two major objectives in the present study. First, to use estradiol valerate to induce selective lesions of endorphinergic perikarya in adult rats in order to assess its effect on alcohol intake. Voluntary alcohol consumption was significantly increased in rats treated with estradiol valerate compared to vehicle, but was not associated with changes in basal levels of anxiety or hypothalamic beta-endorphin content.<br>Second, to use microdialysis to determine the effect of alcohol on extracellular levels of opioid peptides and catecholamines in the nucleus accumbens of awake freely-moving animals. The nucleus accumbens is heavily implicated in alcohol abuse. Four sets of experiments were conducted: (1) Various doses of alcohol (0.0-2.4 g ethanol/kg body weight) were tested on beta-endorphin and catecholamine release in the nucleus accumbens. Only the 2.4 g/kg dose significantly increased levels of dopamine and beta-endorphin. (2) The release of beta-endorphin was assessed in response to stress and alcohol in the nucleus accumbens and hypothalamus. The results showed a different profile for both stimuli: stressors had an immediate effect in the hypothalamus, while alcohol had a latent effect in the nucleus accumbens. (3 & 4) Various doses of alcohol (0.0-3.2 g ethanol/kg body weight) were assessed on extracellular levels of Met-enkephalin and dynorphin A in the nucleus accumbens. While the 1.6 g/kg dose induced the greatest release of Met-enkephalin, the 3.2 g/kg dose induced the greatest release of dynorphin.<br>In conclusion, although estradiol valerate affected alcohol preference, the results did not support the involvement of beta-endorphin. On the other hand, opioid peptides are differentially released in the nucleus accumbens in response to alcohol. The findings lend support to the hypothesis that endogenous opioids mediate some of the effects of alcohol.

Endometriosis is a chronic inflammatory disease that affects 1 in 10 women of childbearing age. It is characterized by the growth of endometrium in extrauterine locations and is associated with chronic pelvic pain, infertility, emotional distress and loss of working ability. Current clinical management provides unsatisfactory outcomes. Thus, the development of more effective therapeutic strategies is still an unmet clinical need, and their development relies on the establishment of animal models that recapitulate the features of endometriosis. The present Thesis has characterized a surgical model of endometriosis that shows nociceptive, affective-like behaviors and impaired cognition, reproducing the symptoms observed in endometriosis patients. In this model of endometriosis, natural cannabinoids alleviate nociceptive behaviors, restore cognitive function and inhibit the development of endometriotic growths. A kappa opioid receptor agonist also shows pain-relieving properties in this model, although affective and cognitive disturbances persist regardless of the pain alleviation. A minimally invasive model of endometriosis that also mimics the symptoms of human endometriosis revealed that minimal endometriosis leads to neuroinflammation in the central nervous system.<br>La endometriosis es una enfermedad inflamatoria crónica que afecta a 1 de cada 10 mujeres en edad fértil. Se caracteriza por el crecimiento de tejido endometrial fuera del útero y se asocia con dolor pélvico crónico, infertilidad, alteraciones emocionales y disminución de la capacidad de trabajo. Los tratamientos actuales proporcionan resultados insatisfactorios. Por lo tanto, se necesitan estrategias terapéuticas más eficaces y su desarrollo depende de la disponibilidad de modelos animales que recapitulen las características de esta enfermedad. La presente Tesis ha caracterizado un modelo quirúrgico de endometriosis que muestra alteraciones nociceptivas, afectivas y cognitivas, reproduciendo los síntomas de la endometriosis. En este modelo, el tratamiento con fitocannabinoides alivia las manifestaciones nociceptivas, restaura la función cognitiva e inhibe el desarrollo del tejido endometrial ectópico. El tratamiento con un agonista del receptor opioide kappa también reduce las manifestaciones nociceptivas de este modelo, aunque no modifica las alteraciones afectivas y cognitivas. Se ha utilizado un modelo mínimamente invasivo, que también reproduce los síntomas de la endometriosis, para explorar los cambios neuroinflamatorios inducidos por la presencia de células endometriales ectópicas. En este modelo, la endometriosis mínima-leve provoca neuroinflamación en el sistema nervioso central.

Neuropathic pain is a complex disorder that includes nociceptive, emotional and cognitive manifestations. This work was focused on how inter-individual variability and endogenous opioid system may be associated with these manifestations. For this purpose, we first validated behavioural paradigms to measure the emotional and cognitive manifestations. Then, we evaluated the influence of specific behavioural traits as well as the role of preproenkephalin (Penk) on neuropathic pain manifestations. We found that time-dependent consequences of neuropathic pain were detected by classical paradigms to evaluate anxiety and depressive-like behaviours, and cognitive function in mice. Amygdalar Pdyn and Gadd45 genes were identified as biomarkers of the influence of anxiety and depression traits on neuropathic pain manifestations. Penk deletion produced a ceiling behavioural effect in anxiety and cognition after neuropathic pain that was related with the maintained amygdalar expression of Pdyn KOR, Npas4 and Nr3c1 and with hippocampal decreased expression of Nr3c1 respectively. In this work, classical behavioural paradigms were capable to detect the influence of behavioural traits and the role of preproenkephalins in nociceptive, emotional and cognitive manifestations of neuropathic pain. These pain manifestations were influenced by anxiety and depression traits. Finally, preproenkephalin was identified as a key component in the development of physiological and behavioural changes induced by neuropathic pain.<br>El dolor neuropático es un trastorno complejo que incluye manifestaciones nociceptivas, emocionales y cognitivas. En este trabajo se estudió cómo la variabilidad interindividual y el sistema opioide endógeno se asocian a estas manifestaciones. Para ello, primero se validaron varios modelos clásicos de comportamiento para evaluar las respuestas emocionales y cognitivas. Después, evaluamos la influencia de los rasgos específicos de comportamiento, así como el papel de la preproencefalinas (Penk) en las manifestaciones del dolor neuropático inducido por ligadura parcial del nervio ciático en ratones. Se observó que era posible detectar las manifestaciones del dolor neuropático dependientes del tiempo a través de paradigmas clásicos utilizados para evaluar comportamientos como la ansiedad, la depresión y la función cognitiva. Se identificaron los genes Pdyn y Gadd45 en amígdala como biomarcadores de la influencia de los rasgos de ansiedad y depresión en las manifestaciones del dolor neuropático. La deleción de Penk produjo un efecto techo en el desarrollo de ansiedad y déficits cognitivos producidos por el dolor neuropático. Este efecto techo se relacionó con el mantenimiento de la expresión de Pdyn, KOR, Npas4 y Nr3c1 en la amígdala y con la disminución en la expresión de Nr3c1 en el hipocampo, respectivamente. En la presente tesis, a través de paradigmas clásicos de comportamiento, se detectó la influencia de rasgos específicos de comportamiento y el papel de las preproencefalinas en las manifestaciones nociceptivas, emocionales y cognitivas asociadas a dolor neuropático. Estas manifestaciones fueron sensibles principalmente a la ansiedad y depresión. Finalmente, se identificó la preproencefalina como un componente esencial para el desarrollo de los cambios fisiológicos y comportamentales inducidos por el dolor neuropático.

An investigation of the interaction of stable opioid/ligands and unstable opioid peptides with opioid receptors in guinea pig brain, guinea pig myenteric plexus and mouse vas deferens has been carried out. The initial aim of the study was to further characterise K opioid receptors, using binding assays and isolated tissue bioassays. The second aim was to determine the true affinity and potency of small dynorphin peptides for the K opioid receptor and to determine if metabolism of the peptides to non K opioid receptor-preferring products contributes to their observed in vitro pharmacology.

Opioids are responsible for a number of effects but are employed primarily as analgesics. The discovery of endogenous opioids and multiple receptors have led to a better understanding of how analgesics function, and how both opioid receptors and endogenous ligands are regulated. The hypothesis of this dissertation states that levels of endogenous enkephalins are modulated by stress, inflammation and the endogenous peptide cholecystokinin (CCK) to alter the antinociceptive efficacy of μ and, possibly, δ opioids. Endogenous enkephalin release results in either direct antinociception or synergistically enhances the antinociceptive effects of the μ agonist morphine via δ receptors. This thesis will first detail how the administration of exogenous δ compounds can enhance the antinociceptive effects of a μ agonist. Exposure of mice to a cold-water swim-stress (CWSS) paradigm resulted in direct antinociception that was attenuated by opioid antagonists. Exposure to CWSS for a limited amount of time did not produce significant antinociception, but produced a marked enhancement of morphine antinociception. This enhancement was blocked by the administration of δ antagonists and (Leu⁵) enkephalin antisera. An antisense oligodeoxynucleotide was designed from the δ opioid receptor and administered to animals. Animals treated with the δ antisense and exposed to the CWSS paradigm showed a significant decrease in antinociception. Inflammation produced in the hind-paw of the mouse significantly enhanced the antinociceptive effects of morphine that was inhibited by δ antagonists and (Leu⁵) enkephalin antisera. The administration of a selective CCK(B) antagonist, L365,260 or CCK(B) antisense, enhances the antinociceptive potency of morphine. This enhancement is attenuated by δ antagonists, (Leu⁵) enkephalin antisera, as well as exhibits a two-way cross tolerance with δ agonists. L365,260 and an "enkephalinase" inhibitor, when coadministered, produced significant antinociception that was blocked by a δ antagonist and (Leu⁵) enkephalin antisera. Using polymerase chain reaction in search of a δ opioid receptor subtype, an orphan receptor was cloned and characterized as a member of the G protein-coupled receptor family. These data suggest that stress results in the release of (Leu⁵) enkephalin that enhances the antinociceptive effects of a μ-selective agonist morphine. Release of endogenous enkephalins may be regulated by the interactions of cholecystokinin at the CCK(B)receptor. Such information may lead to appropriate use of opiates in conjunction with CCK antagonists for the management of appropriate pain states.

Injury causes increased pain sensation in humans and animals but the mechanisms underlying the emergence of persistent pathological pain states, which arise in the absence of on-going physical damage, are unclear. Therefore, elucidating the physiological regulation of such intractable pain is of exceptional biomedical importance. It is well known that endogenous activation of µ-opioid receptors (MORs) provides relief from acute pain but the consequences of prolonged endogenous opioidergic signaling have not been considered. Here we test the hypothesis that the intrinsic mechanisms of MOR signaling promote pathological sensitization of pain circuits in the spinal cord. We found that tissue inflammation produces agonist-independent MOR signaling in the dorsal horn of the spinal cord, which tonically represses hyperalgesia for months, even after complete recovery from injury and re-established normal pain thresholds. Disruption of this constitutive activity with MOR inverse agonists reinstated pain and precipitated cellular, somatic and aversive signs of physical withdrawal. This phenomenon required N-methyl-D-aspartate receptor activation of calcium-sensitive adenylyl cyclase type 1. Thus, we present a novel mechanism of long-lasting opioid analgesia that regulates the transition from acute to chronic pain while, in parallel, generates physical dependence. In conclusion we propose that the prevalence of chronic pain syndromes may result from a failure in constitutive signaling of spinal MORs and a loss of endogenous analgesic control.

Crohn's disease and ulcerative colitis (UC), two types of inflammatory bowel disease (IBD), and idiopathic slow transit constipation (ISTC) are serious diseases of the digestive system with unknown aetiologies. Since it is well known that opioids have a profound effect on the gastrointestinal tract, and also play an important role in immune regulation, it is postulated that they may be involved in the pathophysiology of these debilitating disorders. In this investigation immunohistochemical techniques were used to determine a potential role for opioids in intestinal disease by evaluating the abundance and localisation of the four opioid receptors; DOR, KOR, MOR and ORLl, in full thickness sections of colon from Crohn's disease, UC and ISTC patients, compared to healthy specimens. The endogenous ligand for ORLl, nociceptin, was also investigated, and Tiffalyzer software was used for semi-quantification of the areas of immunoreactivity in the submucosal and myenteric plexuses.